Coronis Neurosciences

Company Overview

Snapshot

Founded in January 2014, Coronis Neurosciences operated with 1–10 employees, focusing on developing therapies for neurocognitive and neurodegenerative disorders. The company secured funding across one seed round from ADNP-KRF. In February 2018, Coronis Neurosciences received FDA Orphan Drug Status for Davunetide, a significant regulatory milestone for its therapeutic pipeline.

Business overview

Coronis Neurosciences is a specialty pharmaceutical company dedicated to the development of therapies for neurocognitive and neurodegenerative disorders. The company's core technology involves a pipeline of clinical- and preclinical-stage molecules, including CP201, a trans-nasally delivered peptide (NAP) for ADNP syndrome, and CP101, a proprietary small peptide for cognitive impairment associated with schizophrenia (CIAS). Coronis Neurosciences primarily serves the pharmaceutical and biotechnology sectors, targeting patients with rare neurogenetic diseases and neurocognitive conditions.

Strategic signal

In February 2018, Coronis Neurosciences received FDA Orphan Drug Status for Davunetide. This designation is a critical validation of the therapeutic potential of Davunetide for rare diseases, signaling to investors and the industry the company's progress in addressing unmet medical needs and potentially accelerating its path through clinical development and market access.

Company Intelligence Q&A

What is Coronis Neurosciences' primary focus?

Coronis Neurosciences specializes in the development of therapies for neurocognitive and neurodegenerative disorders, utilizing a pipeline of clinical- and preclinical-stage molecules.

Which specific conditions does Coronis Neurosciences' pipeline address?

The company's pipeline includes CP201 for ADNP syndrome, an autism spectrum disorder, and CP101, a drug designed to treat cognitive impairment associated with schizophrenia (CIAS).

When did Coronis Neurosciences receive FDA Orphan Drug Status for Davunetide?

In February 2018, Coronis Neurosciences received FDA Orphan Drug Status for Davunetide.

What was the last known operational status of Coronis Neurosciences?

Coronis Neurosciences ceased to operate in May 2022.